touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • Video 3: MDT perspectives on identifying and managing key ADC treatment toxicities in patients with metastatic breast cancer

    Listen to key experts from a multidisciplinary team consider the strategies to avoid, mitigate, identify and effectively manage side effects associated with ADCs in patients with metastatic breast cancer.

    The multidisciplinary team

    • Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France
    • Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA
    • Clinical oncology pharmacy specialist: Dr Scott Edwards, Dr. H. Bliss Murphy Cancer Center, St. John’s, Newfoundland, Canada

      • This touchPODCAST is for HCPs outside of the UK only. 

      This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

      This activity is jointly provided by USF Health and touchIME.

      touchIME is an EBAC® accredited provider.

      For further information visit our website: www.touchONCOLOGY.com

      12 min
    • Video 2: MDT perspectives on communicating ADC treatment toxicities to patients with metastatic breast cancer

      Listen to key experts from a multidisciplinary team discuss effective strategies for communicating the potential side effects associated with ADC treatment to patients with metastatic breast cancer.

      The multidisciplinary team

      • Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France
      • Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA
      • Patient advocate: Mrs Lesley Turner, Independent Cancer Patients’ Voice, UK

        • This touchPODCAST is for HCPs outside of the UK only. 

        This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

        This activity is jointly provided by USF Health and touchIME.

        touchIME is an EBAC® accredited provider.

        For further information visit our website: www.touchONCOLOGY.com

        14 min
      • Video 1: MDT perspectives on the safety profiles of current and emerging ADCs in metastatic breast cancer

        Listen to key experts from a multidisciplinary team review and discuss the safety profiles of current and emerging ADCs in patients with metastatic breast cancer.

        The multidisciplinary team

        • Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France
        • Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA

          • This touchPODCAST is for HCPs outside of the UK only. 

          This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

          This activity is jointly provided by USF Health and touchIME.

          touchIME is an EBAC® accredited provider.

          For further information visit our website: www.touchONCOLOGY.com

          12 min
        • Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease

          touchEXPERT FOCUS for touchOPHTHALMOLOGY

          Listen to retina specialist Prof. Peter Kaiser answer a series of questions on the current clinical landscape for neovascular age-related macular degeneration and diabetic macular oedema, share his perspective on how newly available treatments are influencing the existing standard of care and provide guidance on how new therapies can be effectively integrated into clinical practice.

          The expert

          • Prof. Peter Kaiser, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA

            • This touchPODCAST is for HCPs outside of the USA and UK only.


            This activity is funded by an independent medical education grant from Bayer Consumer Care AG.

            The activity is provided by touchIME.
            touchIME is an EBAC® accredited provider.

            For further information visit our website:
            https://touchophthalmologyime.org/adopting-emerging-therapies-for-retinal-diseases

            20 min
          • Expanding horizons for patients with Pompe disease: Using data to guide clinical practice

            touchCONGRESS for touchCARDIO

            Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

            Overview

            •       Data reviews with Prof. Mozaffar,
            •       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

              • Clinical themes

              1. Clinical and real-world data on long-term outcomes in Pompe disease
              2. Outcomes and impact of treatment switching in Pompe disease
              3. Latest clinical data on current and emerging therapies in Pompe disease

                4. The internationally renowned Pompe disease expert faculty

                •       Prof. Tahseen Mozaffar, Irvine, CA, USA
                •       Dr Jennifer L Cohen, Durham, NC, USA
                •       Prof. Benedikt Schoser, Munich, German

                  • This touchPODCAST is for HCPs outside of the UK only.

                  This activity is funded by an independent medical education grant from Amicus Therapeutics.


                  This activity is jointly provided by USF Health and touchIME.
                  touchIME is an EBAC® accredited provider.

                  For further information visit our website:

                  1 hr 7 min
                • Expanding horizons for patients with Pompe disease: Using data to guide clinical practice

                  touchCONGRESS for touchENDOCRINOLOGY

                  Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

                  Overview

                  •       Data reviews with Prof. Mozaffar,
                  •       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

                    • Clinical themes

                    1. Clinical and real-world data on long-term outcomes in Pompe disease
                    2. Outcomes and impact of treatment switching in Pompe disease
                    3. Latest clinical data on current and emerging therapies in Pompe disease

                      4. The internationally renowned Pompe disease expert faculty

                      •       Prof. Tahseen Mozaffar, Irvine, CA, USA
                      •       Dr Jennifer L Cohen, Durham, NC, USA
                      •       Prof. Benedikt Schoser, Munich, Germany

                        • This touchPODCAST is for HCPs outside of the UK only.

                        This activity is funded by an independent medical education grant from Amicus Therapeutics.

                        This activity is jointly provided by USF Health and touchIME.

                        touchIME is an EBAC® accredited provider.

                        For further information visit our website:

                        1 hr 7 min
                      • Expanding horizons for patients with Pompe disease: Using data to guide clinical practice

                        touchCONGRESS for touchNEUROLOGY

                        Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

                        Overview

                        •       Data reviews with Prof. Mozaffar,
                        •       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

                          • Clinical themes

                          1. Clinical and real-world data on long-term outcomes in Pompe disease
                          2. Outcomes and impact of treatment switching in Pompe disease
                          3. Latest clinical data on current and emerging therapies in Pompe disease

                            4. The internationally renowned Pompe disease expert faculty

                            •       Prof. Tahseen Mozaffar, Irvine, CA, USA
                            •       Dr Jennifer L Cohen, Durham, NC, USA
                            •       Prof. Benedikt Schoser, Munich, Germany

                              • This touchPODCAST is for HCPs outside of the UK only.

                              This activity is funded by an independent medical education grant from Amicus Therapeutics.

                              This activity is jointly provided by USF Health and touchIME.

                              touchIME is an EBAC® accredited provider.

                              For further information visit our website:

                              1 hr 7 min
                            • Expanding horizons for patients with Pompe disease Using data to guide clinical practice

                              touchCONGRESS for touchRESPIRATORY

                              Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

                              Overview

                              •       Data reviews with Prof. Mozaffar,
                              •       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

                                • Clinical themes

                                1. Clinical and real-world data on long-term outcomes in Pompe disease
                                2. Outcomes and impact of treatment switching in Pompe disease
                                3. Latest clinical data on current and emerging therapies in Pompe disease

                                  4. The internationally renowned Pompe disease expert faculty

                                  •       Prof. Tahseen Mozaffar, Irvine, CA, USA
                                  •       Dr Jennifer L Cohen, Durham, NC, USA
                                  •       Prof. Benedikt Schoser, Munich, Germany

                                    • This touchPODCAST is for HCPs outside of the UK only.

                                    This activity is funded by an independent medical education grant from Amicus Therapeutics.

                                    This activity is jointly provided by USF Health and touchIME.

                                    touchIME is an EBAC® accredited provider.

                                    For further information visit our website:

                                    1 hr 7 min
                                  • MDT perspectives on the importance of patient engagement in PARPi use - Video 3

                                    touchMDT for touchONCOLOGY

                                    Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors.

                                    The multidisciplinary team and patient advocate:

                                    Medical oncologist – Dr Alicia Morgans

                                    Dana-Farber Cancer Institute, Boston, Massachusetts, USA

                                    Nurse practitioner – Dr Grace Cullen

                                    John D. Dingell VA Medical Center, Detroit, Michigan, USA

                                    Patient Advocate – Mr Tony Collier

                                    Tackle Prostate Cancer, London, UK

                                    This touchPODCAST is for HCPs outside of the UK only.

                                    This activity is supported by an independent medical education funding request from AstraZeneca.

                                    This activity is jointly provided by USF Health and touchIME.

                                    touchIME is an EBAC® accredited provider.

                                    For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

                                     

                                    14 min
                                  • MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2

                                    touchMDT for touchONCOLOGY  

                                    Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.  

                                    The multidisciplinary team:

                                    Medical oncologist – Dr Alicia Morgans

                                    Dana-Farber Cancer Institute, Boston, Massachusetts, USA

                                    Nurse practitioner – Dr Grace Cullen

                                    John D. Dingell VA Medical Center, Detroit, Michigan, USA

                                    Pathologist – Prof. Albrecht Stenzinger

                                    University of Heidelberg, Heidelberg, Germany

                                    This touchPODCAST is for HCPs outside of the UK  only.

                                    This activity is supported by an independent medical education funding request from AstraZeneca.

                                    This activity is jointly provided by USF Health and touchIME.

                                    touchIME is an EBAC® accredited provider.

                                    For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

                                    14 min

                                  About touchPODCAST

                                  From the publisher's feed

                                  Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.